IDO1 and endometrial cancer: Multiple lines of evidence link IDO1 expression with poor prognosis in patients, including those diagnosed with acute myeloid leukemia [9], non-small cell lung cancer [10], colorectal cancer [11], prostate cancer [12], endometrial cancer [13], ovarian cancer [14], and EC [15].